Marinomed Biotech, a globally active biopharmaceutical company with headquarters in Vienna, and the renowned University of Utah have published scientific investigations that provide initial evidence for further significant benefits of the innovative Marinosolv platform in the field of corneal eye diseases. The study is now available to read in the international journal IOVS (Investigative Ophthalmology & Visual Science). The new data show the effectiveness and manifold scope of application of the clinically validated Marinosolv platform. This confirms again that Marinosolv allows to apply a known drug in a new indication with remarkable potential advantages for patients, says Dr. Andreas Grassauer, CEO of Marinomed.
Marinosolv was identified as a feasible aqueous drug carrier with distinct advantages for the frequent formulation of pergolide as eye drops. Pergolide is currently not used for the treatment of eye diseases because the application is hampered by its poor solubility. The now published study revealed that pergolide solubilized by Marinosolv could be a potentially efficacious therapeutic approach for the restoration of corneal sensation and visual acuity loss due to neurotrophic keratopathy (degenerative disease of the cornea of the eye).
Bala Ambati, MD, PhD, of the University of Utah said, Solubilization of otherwise insoluble compounds is critical especially in eye care where compounds are washed out fast. Marinosolv is a new aqueous drug carrier that deserves further investigation beyond our present study.
Neurotrophic keratopathy is a degenerative disease of the cornea that results in decreased or absent sensation to the cornea, corneal thinning, poor healing after corneal injury, persistent epithelial defects, cornea melting or perforation, and loss of vision. It can be caused by herpes virus, chemical burns, physical injury, corneal surgery, long term contact lens wear, or nerve injury. Neurotrophic keratopathy has an estimated prevalence of five in 10,000 people (0.05%).